Exact Sciences, competitor claim victories as court case continues 

Exact Sciences, the Madison-based cancer detection company, and competitor Geneoscopy, a life sciences company in Missouri, both claimed wins as litigation between the two about their colon cancer screening tests continues.

Exact Sciences filed a lawsuit in 2023 against Geneoscopy, alleging the company infringed on patents for Cologuard by creating a test called ColoSense.

Geneoscopy lauded a decision by Exact Sciences last week to withdraw a motion that sought to prevent the commercialization of ColoSense. CEO Andrew Barnell said the move “confirms what we have said all along — ColoSense is grounded in innovation, not infringement.”

“Competition fosters scientific progress and improves patient care,” he said. “We are excited to continue moving ColoSense forward, bringing a new and patient-friendly cancer screening option to market that enhances early detection and saves lives.”

In response, Exact Sciences said the court denied a request by Geneoscopy to stay litigation, thus “agreeing that our patent infringement, false advertising and unfair competition claims should proceed with discovery so that we can stay on track for a trial next year.”

Exact Sciences said it withdrew its request to block commercialization of ColoSense to “preserve its ability to refile” after review of patents by the U.S. Patent and Trademark Office.

“We look forward to presenting our case in court to put an end to Geneoscopy’s continued attempts to mislead the public,” they said.

This article first appeared in the Wisconsin Health News daily email newsletter. Sign up for your free trial here.